Evidence map›Paper›PMID 36794509›Full record

ArticleHaematologica2023

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.

Maymona G Abdelmagid, Aref Al-Kali, Kebede H Begna, William J Hogan, Mark R Litzow, Farah Fleti, Abhishek A Mangaonkar, Mrinal S Patnaik, Michelle A Elliott, Hassan Alkhateeb and 8 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Maymona G AbdelmagidDivisions of Hematology and Medicine.
Aref Al-KaliDivisions of Hematology and Medicine.
Kebede H BegnaDivisions of Hematology and Medicine.
William J HoganDivisions of Hematology and Medicine.
Mark R LitzowDivisions of Hematology and Medicine.
Farah FletiDivisions of Hematology and Medicine.
Abhishek A MangaonkarDivisions of Hematology and Medicine.
Mrinal S PatnaikDivisions of Hematology and Medicine.
Michelle A ElliottDivisions of Hematology and Medicine.
Hassan AlkhateebDivisions of Hematology and Medicine.
Min ShiDivisions of Hematopathology, Departments of Laboratory Medicine, Mayo Clinic, Rochester, MN.
Matthew T HowardDivisions of Hematopathology, Departments of Laboratory Medicine, Mayo Clinic, Rochester, MN.
Kaaren K ReichardDivisions of Hematopathology, Departments of Laboratory Medicine, Mayo Clinic, Rochester, MN.
Rhett P KetterlingDivisions of Hematopathology, Departments of Laboratory Medicine, Mayo Clinic, Rochester, MN.
Mithun ShahDivisions of Hematology and Medicine.
Animesh PardananiDivisions of Hematology and Medicine.
Naseema GangatDivisions of Hematology and Medicine.
Ayalew TefferiDivisions of Hematology and Medicine. tefferi.ayalew@mayo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Blast CrisisMyeloproliferative DisordersHumansMutationNitrilesPyrazolesPyrimidinesNitrilesPyrazolesPyrimidinesruxolitinib

Identifiers

PMID36794509
PMCPMC10483339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.